Teva Pharmaceutical cash flow strength cuts chances of M&A loan
Israeli generic drugmaker Teva Pharmaceutical’s $6.8bn takeover of US based Cephalon may involve a syndicated loan, although the bond markets and strong internal cash flow are strong potential funding sources, according to loans bankers close to the borrower.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
